Trials / Completed
CompletedNCT00343148
Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid
Pharmacokinetic Study of AVI-4126 in Cerebral Spinal Fluid Among Healthy Adult Males Following Intravenous Administration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (planned)
- Sponsor
- Sarepta Therapeutics, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
Because AVI-4020 Injection was found to cross the blood-brain barrier, and because AVI-4126 (RESTEN-NG) has potential medical benefit to people with a variety of diseases, including cancers, this study is being performed to find out if AVI-4126 also crosses the blood-brain barrier. If it does, then additional investigations could be performed, such as in people with certain types of cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVI-4126 Injection (RESTEN-NG®) |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2006-06-01
- Completion
- 2009-06-01
- First posted
- 2006-06-22
- Last updated
- 2009-07-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00343148. Inclusion in this directory is not an endorsement.